On Jan. 06, O’Brien Patrick divested U.S. $1,810,346 in shares of Arrowhead Pharmaceuticals Inc.. The GC sold 25,000 shares at a price per share of $72.41. The transaction decreased this specific insider’s holdings to 293,375 shares worth around $23.31 million at present.
Another 30,625 shares were sold by Myszkowski Kenneth Allen, for more than $2,218,477 in total proceeds. The CFO dumped the shares at a price of $72.44 and the insider now owns almost 457,043 shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
That same day, Hamilton James C sold 38,750 shares. The Senior Vice President divested U.S. $2,809,578 in shares of Arrowhead Pharmaceuticals Inc. at a price per share of $72.51. The transaction decreased this specific insider’s holdings to 136,250 shares worth around $10827787.5 at present.
Robert W. Baird took its Arrowhead Pharmaceuticals Inc. [ARWR] rating to the equivalent of a Neutral from an Outperform, and the price target to $75, in a research note dated December 21, 2020. That figure represents around a -5.96% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Robert W. Baird’s analysts downgrading the shares from “an Outperform” rating to “a Neutral” rating in a research note to investors issued in late December. Meanwhile, UBS had launched its coverage on ARWR with “Buy”, in a research note produced for clients December 16, 2020. In addition, there was a new coverage from Citigroup on November 19, 2020. The research firm rated ARWR “a Buy”.
Is Arrowhead Pharmaceuticals Inc. [NASDAQ:ARWR] a Good Buy Right Now?
It should be noted that ARWR technical indicators for short, intermediate as well as long term progress have placed an overall average of 100% as Buy. The average signal changed from 100% Buy in the last week and compares with 72% Buy in the past month. Data from Arrowhead Pharmaceuticals Inc.’s Trend Spotter indicated that the signals were Strongest. The stock current average is 1.12 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 1.1 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 1.41 million shares.
ARWR Price Performance
On Wall Street, Arrowhead Pharmaceuticals Inc. [NASDAQ:ARWR] finished Thursday’s session up 6.84% at $79.47. The stock went up to $79.49 at the same session while its lowest single day price was $75.00. In the last five days, it saw a rise of about 2.63%, Arrowhead Pharmaceuticals Inc. shares gained by almost 3.57% since the beginning of the year. However, the share price has dropped to as low as -8.39% below its one year high. On 01/07/21, the company shares recorded $79.49, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/06/21, the same year at $70.11. The company’s shares have inclined by 32.89% in the past year. The 50-day SMA achieved is $69.92 while the 200-day SMA is $47.63. Volume dropped to 0.99 million from 1.72 million in the previous session.
ARWR Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 76.48 level, and in case of violation of this particular level, it will cause more drop to 73.50 level. On the upper level, 82.48 is still the key resistance. The stock may increase to the subsequent resistance at 80.97. The Relative Strength Index (RSI) pinned on the 14-day chart is 59.84, implying a neutral technical stance while the MACD stands at -3.61, meaning price will decrease in the next trading period. Percent R indicator moved to 43.75%, implying low price movement. Stochastic %K at 31.76% suggest holding the stock.
What is the short interest in Arrowhead Pharmaceuticals Inc.?
Short interest in the Arrowhead Pharmaceuticals Inc. stock has surged, increasing by 0.81 million shares to total 7.39 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 8.2 million, data from Yahoo Finance shows. The decrease of -10.96% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 9.89% of the overall float for the stock.
Arrowhead Pharmaceuticals Inc.’s Biggest Shareholders: Who Owns Arrowhead Pharmaceuticals Inc. [ARWR]?
Filings by BlackRock Fund Advisors showed that the firm now holds a total of 11,183,942 shares or roughly 10.88% of the outstanding ARWR shares. This means their shares have reduced by -370,402 from the 11,183,942 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, The Vanguard Group, Inc. updated stake is worth $551,298,246. Details in the latest 13F filings reveal that SSgA Funds Management, Inc. disposed off their -7.12% stake valued at $284,081,544 while Invesco Advisers, Inc. cut theirs at $187,621,265. During the last quarter, SSgA Funds Management, Inc. liquidated -348,323 of its shares in Arrowhead Pharmaceuticals Inc. while Invesco Advisers, Inc. sold -900 shares. The Fidelity Management & Research Co’s holdings currently number 1,892,656 shares at $150409372.32. According to the firm’s last 13F report, Northern Trust Investments, Inc. shares in the company at filing stood at 1,595,308 shares, roughly $99,754,609.
ARWR Earnings Forecast For The Current Quarter
Arrowhead Pharmaceuticals Inc. [ARWR] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $79.46M and an earnings per share of $0.14 for Dec 2020. Looking further ahead, the company is expected to report revenue of $34.16M at an EPS of -$0.25 for Mar 2021. The estimates represent upside of -8.00% and -224.10% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
ARWR Earnings Estimates For The Current Year
For the financial year, Arrowhead Pharmaceuticals Inc. [NASDAQ:ARWR] is expected to bring in revenue of $211.45M. The returns are nearly $123.46 million higher than the company’s actual revenue recorded in the fiscal year 2020. In terms of EPS for the 2021, estimate put it at -0.24, higher than that of FY20 by $0.6. Estimates put this year’s earnings growth at 71.40%, -283.30% for the next, and at an annual 7.33% over the next 5-year period. As for sales, forecasts are for an increase of 140.30% in the current fiscal year and a further -8.00% over the following year.
What are analyst thoughts on Arrowhead Pharmaceuticals Inc.?
Looking forward to the Arrowhead Pharmaceuticals Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Arrowhead Pharmaceuticals Inc. stock at $90.00 within the next 12 months, which represents almost 11.7 per cent growth from its previous closing price of $79.47. The highest analysts’ target for Arrowhead Pharmaceuticals Inc. stock projections is $100.00 and the lowest one is $34.00. Still, 12 analysts sharing their consensus rating for ARWR stock in 2021 agree that it is an Overweight.